J Clin Endocrinol Metab:男性睾酮浓度低下可能和缺血性卒中发生风险相关

2015-11-05 phylis 译 MedSci原创

目的:内源性性激素和缺血性卒中(IS)的关系尚不清楚。研究者提出假设内源性激素溶度与一般人群中IS发生的风险相关。实验设计:在1981-83的丹麦哥本哈根市心脏研究中,对成年男性(n = 4615)和女性(n = 4724)进行内源性性激素测定,对其进行了长达29年的随访,无失访。分析评估IS的发生的风险是否通过潜在的调节因子调节。对现在和以前的研究结果进行meta分析。主要预后:应用竞争免疫测定

目的:内源性激素和缺血性卒中(IS)的关系尚不清楚。研究者提出假设内源性激素溶度与一般人群中IS发生的风险相关。

实验设计:在1981-83的丹麦哥本哈根市心脏研究中,对成年男性(n = 4615)和女性(n = 4724)进行内源性性激素测定,然后进行了长达29年的随访,无失访。分析评估IS的发生的风险是否通过潜在的调节因子调节。对现在和以前的研究结果进行meta分析。

主要预后:应用竞争免疫测定血浆总睾酮和总雌二醇。IS的诊断是根据丹麦国家患者登记和死亡登记记录,由经验丰富的神经科医师进行验证。

结果:在随访期间,524名男性和563名妇女发生IS。与睾酮浓度较高(11-90百分位)的男性相比,男性睾酮浓度的较低(≤10百分位),IS发生的HR:1.34(95%CI:1.05-1.72);21%的风险由BMI介导和14%的风险由高血压介导。超重/肥胖和高血压男性相应的HR:1.46(1.09-1.95)。荟萃分析中,相应的HR为1.43(1.21-1.70)。其他极端浓度的睾酮或雌二醇与男性或女性的IS风险不相关的。

结论:男性极低的内源性睾酮浓度与IS发生高风险相关,这种风险部分由BMI和高血压介导。低浓度的睾酮是否是IS发生的关键因素,或者仅是不良代谢健康状况的一个生物标志物,仍不清楚。

原文出处:

Holmegard HN1, Nordestgaard BG, Jensen GB,et al. Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses. J Clin Endocrinol Metab. 2015,Oct 28.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806046, encodeId=250d180604612, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Nov 29 19:07:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887474, encodeId=3cb7188e4743f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 10 21:07:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895847, encodeId=cc96189584e77, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Sep 11 17:07:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892700, encodeId=1b871892e0052, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Jun 23 16:07:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544403, encodeId=2c511544403aa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Nov 07 12:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806046, encodeId=250d180604612, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Nov 29 19:07:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887474, encodeId=3cb7188e4743f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 10 21:07:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895847, encodeId=cc96189584e77, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Sep 11 17:07:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892700, encodeId=1b871892e0052, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Jun 23 16:07:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544403, encodeId=2c511544403aa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Nov 07 12:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=)]
    2016-08-10 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806046, encodeId=250d180604612, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Nov 29 19:07:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887474, encodeId=3cb7188e4743f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 10 21:07:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895847, encodeId=cc96189584e77, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Sep 11 17:07:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892700, encodeId=1b871892e0052, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Jun 23 16:07:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544403, encodeId=2c511544403aa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Nov 07 12:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=)]
    2016-09-11 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806046, encodeId=250d180604612, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Nov 29 19:07:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887474, encodeId=3cb7188e4743f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 10 21:07:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895847, encodeId=cc96189584e77, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Sep 11 17:07:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892700, encodeId=1b871892e0052, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Jun 23 16:07:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544403, encodeId=2c511544403aa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Nov 07 12:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806046, encodeId=250d180604612, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Nov 29 19:07:00 CST 2015, time=2015-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887474, encodeId=3cb7188e4743f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Aug 10 21:07:00 CST 2016, time=2016-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895847, encodeId=cc96189584e77, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Sep 11 17:07:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892700, encodeId=1b871892e0052, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Jun 23 16:07:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544403, encodeId=2c511544403aa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Nov 07 12:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=)]

相关资讯

Neurotox Res:缺血性卒中患者尿酸的预测价值

心血管疾病或卒中患者中,血清尿酸(UA)的重要性和功能尚不清楚。研究人员旨在评估卒中患者的UA水平以及内源性UA与急性缺血性卒中(AIS)患者临床预后的相关性,尤其是性别和UA水平与AIS预后可能的关系。研究人员筛选了缺血性卒中48h内的患者303名,101名患者进行了溶栓治疗。入院后第二天清晨测量血清UA(μmol/L)。患者预后用发病后90天mRS评估。根据血清UA水平,将患者分为四组。应用二

Diabetologia:生儿子的人妊娠期糖尿病风险更高?

妊娠期间的糖尿病有两种情况,一种为妊娠前已确诊患糖尿病,称“糖尿病合并妊娠”;另一种为妊娠前糖代谢正常或有潜在糖耐量减退、妊娠期才出现或确诊的糖尿病,又称为“妊娠期糖尿病(GDM)”。糖尿病孕妇中80%以上为GDM,糖尿病合并妊娠者不足20%。GDM发生率世界各国报道为1%~14%,我国发生率为1%~5%,近年有明显增高趋势。最近有研究表明男性胎儿会降低孕妇胰岛β细胞功能,从而增加妊娠期糖尿病(G

Radiology:心脏退化程度也分性别!!!!

通过每隔一定的时间对人们的心脏进行动态成像扫描,研究人员发现,随着时间的流逝,男性和女性的心脏泵血功能不同,因此,今后治疗男性和女性心力衰竭可能会有两种不同的治疗方案。约翰霍普金斯大学的研究人员将其发表在Radiology杂志上。这项研究是研究人员第一次使用MRI对人们的心脏功能随时间变化发生的变化进行调查的研究。 通过对近3000名成人功能衰退的心脏进行MRI检查,主要研究目标是左心室的泵血功能

Blood:霍奇金淋巴瘤患者近亲的各自风险评估

家族性霍奇金淋巴瘤(HL)的罕见性阻碍了家族聚集性分析。我们的目的是发现HL的家族性风险,包括家庭关系、组织学、诊断时的年龄和性别。试验计算了在欧洲五个国家,从1955年至2009年间被诊断的13922霍奇金淋巴瘤患者的57475名一级亲属HL的发病率。标准化发病率(SIR)计算方法采用组织学、年龄、性别、周期和国家特定的发病率作为参考。还计算了一生的累积风险(CR)。HL患者一级亲属的HL整体累

Stroke:检测斑块类型,识别高风险卒中患者

背景和目的:这篇研究的目的是为了分析人类颈动脉斑块的形态和患者性别,年龄以及神经系统症状史的相关性。方法:这篇研究包括2004年到2013年间,763名存在粥样硬化患者颈动脉狭窄术后取下的斑块。颈动脉斑块的形态学分析评估斑块的类型,斑块的稳定性,钙化的程度,炎症以及血管再生和胶原蛋白和弹性蛋白的沉积。根据预后的评估,logistic回归,有序回归,多分类回归分析。校正常见粥样硬化的危险因素。结果:

Int J Epidemiol:男女吸烟相关肿瘤风险几乎没差异

过去的美国女性开始吸烟的年龄通常迟于男性,并且吸烟相关癌症风险也低于男性。不过现在越来越多的出生队列研究提示女性和男性吸烟史越来越接近,并且出现了肿瘤高危险年龄段人群。这些变化对肿瘤的发生情况的影响目前还没有系统的探究过。研究者对该问题进行了一项研究,共纳入了186 057名女性和266 074 名男性,在1995年纳入研究时参与者年龄在50-71之间,对其随访11年。该队列的参与者出生于1924